Lupin Q4 FY26: Nuvama Downgrades to Hold, TP Rs 2,600

What changed for Lupin investors

Lupin Ltd is back in focus after a sharp mix of strong quarterly performance and cautious brokerage commentary. Nuvama Institutional Equities downgraded the stock to “Hold” from “Buy” even as Lupin delivered strong profit growth in Q4 FY26 and beat Street expectations “on all fronts”. Nuvama said the downgrade reflects limited upside left after a recent uptick in the stock. It also trimmed its 12-month view by changing its target price. The call comes at a time when other brokerages are still constructive, keeping the market split between valuation comfort and earnings momentum.

Nuvama’s downgrade and target price revision

Nuvama’s note explicitly moved Lupin to “Hold” after the recent rally. It set a target price of Rs 2,600 and referenced an earlier target price of Rs 2,550. The brokerage’s core argument was not about a weak quarter, but about what the next phase of growth could look like. Nuvama expects FY27 and FY28 to be transitional years for Lupin, with growth moderating and margins cooling. It also flagged product concentration risk building in the near term. These points, in Nuvama’s view, reduce the scope for further re-rating after the run-up.

Q4 FY26 performance highlights cited by Nuvama

Nuvama acknowledged a strong operating print in Q4 FY26. It said Lupin’s profit after tax (PAT) rose 81% year-on-year in Q4 FY26. It also highlighted a gross margin of 75.2% and an EBITDA margin of 29%. The brokerage attributed the margin strength to a better US product mix and a strong performance in emerging markets. Separately, another market update in the provided data said Lupin recorded a 90% jump in consolidated net profit for the quarter, even as the stock traded lower on the day. Together, these details show that the downgrade is not driven by quarter-specific disappointment.

What Nuvama expects for FY27 and FY28

Nuvama expects the next two years to be a reset phase rather than a straight-line continuation of recent momentum. It said FY27E growth is likely to be in single digits. It also expects EBITDA margins to cool to the 25% to 26% range. In its model updates, Nuvama said it is raising FY27E and FY28E EPS by 3% and 1%, respectively. At the same time, it built in revenue, EBITDA, and PAT growth of 4%, -10%, and -12% CAGR over FY26 to FY28E. These assumptions underline the brokerage’s concern that the earnings mix could become tougher even if the top line grows.

Product concentration risk: gSpiriva, Tolvaptan, Mirabegron

A key reason for the “Hold” view is rising dependence on a few products. Nuvama said Lupin has high reliance on gSpiriva, Tolvaptan, and Mirabegron, and it sees growing product concentration risk in the near term. It also added that “competition in gSpiriva over next 12 months would be a surprise,” indicating that competitive intensity could emerge sooner than expected. For investors, the practical takeaway is that near-term earnings delivery may depend more heavily on performance and pricing in a narrower set of products.

Pipeline optionality pushed out to FY29E

Nuvama also pointed to upcoming launches, but framed them as later-year opportunities. It said promising launches such as bNeulasta Onpro, bEnbrel, and gDulera remain FY29E opportunities. This timing matters because it suggests that some of the pipeline-driven upside is not immediate. If the next two years are “transitional,” as Nuvama expects, the market may focus more on execution in the existing portfolio and on defending margins, rather than pricing in distant launches.

What other brokerages and consensus data indicate

While Nuvama turned cautious, not all brokerages align with that stance. Nomura, as cited in the provided text, maintained a “Buy” and assigned a target price of Rs 2,580. Bloomberg-tracked consensus data in the provided content shows a still-positive distribution: out of 40 analysts, 28 had “buy” calls, eight had “hold” calls, and four had “sell” calls. The same snapshot said the average 12-month target price is Rs 2,434.86, implying an upside potential of 0.4% from the cited trading level of Rs 2,434. These numbers point to a market where upside is seen as limited by some, even if the broader analyst community remains supportive.

Stock levels and key snapshot points in the data

The provided text contains multiple price snapshots across dates and contexts. One cited level showed Lupin shares trading about 1% lower at Rs 2,434. Another section presented a screen-style figure of Rs 2,247.40, down 132.10 or 5.55%. Separately, an early April 2026 snapshot placed Lupin around Rs 2,100, with a 52-week high of Rs 2,611 and a 52-week low of Rs 1,850, along with a 1-year return of -12%. It also cited a market capitalisation of Rs 95,600 crore, a PE of about 28x, and a price-to-book of 5.4x. These mixed snapshots reinforce that the stock has seen meaningful volatility, which can amplify the impact of brokerage revisions.

Key figures at a glance

Why the downgrade matters for the pharma sector narrative

The episode highlights a common pattern in large-cap pharma: strong quarterly delivery can coincide with caution on the forward curve. Nuvama’s stance centres on how sustainable current margins are and how concentrated the earnings drivers may become. For sector watchers, the note also draws attention to product-specific competitive dynamics in the US, which can change profitability quickly. At the same time, the presence of “Buy” ratings and targets near Nuvama’s level suggests the debate is less about business quality and more about valuation comfort and timing. Investors tracking Lupin into the FY27 guidance season may therefore focus on management commentary around margin sustainability and product contribution trends.

Conclusion

Lupin’s Q4 FY26 performance, as described in the provided text, was strong on profitability and margins, but Nuvama’s downgrade to “Hold” signals a tighter risk-reward after the rally. With a revised target price of Rs 2,600 and concerns around product concentration risk, the brokerage is positioning FY27 and FY28 as transitional. Other views, including Nomura’s “Buy” with a Rs 2,580 target and a largely positive Bloomberg analyst distribution, show that the Street is not uniformly cautious. The next key triggers implied in the material are FY27 guidance clarity and how Lupin addresses near-term concentration and competitive risks in its US portfolio.